Published 1 year ago

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge - Viatris (NASDAQ:VTRS)

Summary by Ground News

Viatris will commence a tender offer for $11.00 per share in cash at closing. Oyster Point Pharma launched Tyrvaya, the first and only FDA-approved nasal spray for the signs and symptoms of dry eye disease. The transaction is anticipated to close during the first quarter of 2023.

0 Articles

All

Left

Center

Right

Benzinga

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge - Viatris (NASDAQ:VTRS)

1 year ago·New York, United States

Read Full Article

ophthalmologytimes.com

Oyster Point Pharma to be acquired by Viatris

Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.

1 year ago

Read Full Article

Spotlight Growth

Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share - Spotlight Growth

Viatris (NASDAQ: VTRS) says the acquisition of Oyster Point Pharma (NASDAQ: OYST) will serve as foundation for its new eye health business.

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated1 year agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge - Viatris (NASDAQ:VTRS)

0 Articles

0 Articles

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge - Viatris (NASDAQ:VTRS)

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge - Viatris (NASDAQ:VTRS)

Oyster Point Pharma to be acquired by Viatris

Oyster Point Pharma to be acquired by Viatris

Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share - Spotlight Growth

Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share - Spotlight Growth

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics